Have a personal or library account? Click to login
An Algorithm to Define the Optimum Biological Dose of Metronomic Chemotherapy Cover

An Algorithm to Define the Optimum Biological Dose of Metronomic Chemotherapy

Open Access
|Jun 2018

References

  1. Bhattacharjee A., Patil V.M. (2016): Time-Dependent Area under the ROC Curve for Optimum Biological Dose Detection. Turkiye Klinikleri J Biostat 8: 103-109.10.5336/biostatic.2016-51505
  2. Bhattacharjee A., Patil V.M. (2017): Determining an Optimum Biological Dose of a Metronomic chemotherapy. Journal of Data Science 15(1):77-94.10.6339/JDS.201701_15(1).0005
  3. Briasoulis E., Pappas P., Puozzo C., Tolis C., Fountzilas G., Dafni U. (2009): Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res 15: 6454-6461.10.1158/1078-0432.CCR-09-0970
  4. Cheung Y.K., Chappell R. (2000): Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 56: 1177-1182.10.1111/j.0006-341X.2000.01177.x
  5. DeVita V.T. Jr., Chu E. (2008): A history of cancer chemotherapy. Cancer Res 68: 8643-8653.10.1158/0008-5472.CAN-07-6611
  6. Golfinopoulos V., Salanti G., Pavlidis N., Ioannidis J.P.A. (2007): Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol 8: 898-911.10.1016/S1470-2045(07)70281-4
  7. Hanahan D., Bergers G., Bergsland E. (2000): Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105: 1045-1047.10.1172/JCI987230084210772648
  8. Hobson B., Denekamp J. (1984): Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer 49: 405-413.10.1038/bjc.1984.6619767596201181
  9. Ilie M., Long E., Hofman V., Selva E., Bonnetaud C., Boyer J.(2014): Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer. Br J Cancer 110: 1236-1243.10.1038/bjc.2014.11395086324473396
  10. Kerbel R.S., Kamen B.A. (2004): The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4: 423-436.10.1038/nrc136915170445
  11. Kerbel R.S., Klement G., Pritchard K.I., Kamen B. (2002): Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 13: 12-15.10.1093/annonc/mdf09311863092
  12. Kumar R., Jose J., Vishwakarma G.K., Bhattacharjee A. (2017): Alternative of clinical end point selection for metronomic studies. IJS Short Reports. Medknow Publications and Media Pvt. Ltd 2: 50.10.4103/ijssr.ijssr_10_17
  13. Marmé D., Fusenig N. (2007): Tumor Angiogenesis: Basic Mechanisms and Cancer Therapy. Springer Science & Business Media.10.1007/978-3-540-33177-3
  14. Pantziarka P., Hutchinson L., André N., Benzekry S., Bertolini F., Bhattacharjee A. (2016): Next generation metronomic chemotherapy - Report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6- 8 May 2016, Mumbai. Ecancermedicalscience 10: 689.10.3332/ecancer.2016.689513032827994645
  15. Patil V.M., Noronha V., Joshi A., Muddu V.K., Dhumal S., Bhosale B.(2015): A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Oral Oncol. Elsevier 51: 279-286.10.1016/j.oraloncology.2014.12.00225578869
  16. Saltz L.B. (2008): Progress in cancer care: the hope, the hype, and the gap between reality and perception. J Clin Oncol 26: 5020-5021.10.1200/JCO.2008.17.619818794538
  17. Scharovsky O.G., Mainetti L.E., Rozados VR. (2009): Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol. 16: 7-15.10.3747/co.v16i2.420266923119370174
  18. Schmid P., Schippinger W., Nitsch T., Huebner G., Heilmann V., Schultze W.(2005): Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol 23: 432-440.10.1200/JCO.2005.06.07215659490
  19. Skipper H.E., Schabel F.M. Jr, Mellett L.B., Montgomery J.A., Wilkoff L.J., Lloyd H.H. (1970): Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 54: 431-450.
  20. Vacca A., Iurlaro M., Ribatti D., Minischetti M., Nico B., Ria R.(1999): Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94: 4143-4155.10.1182/blood.V94.12.4143
DOI: https://doi.org/10.2478/bile-2018-0001 | Journal eISSN: 2199-577X | Journal ISSN: 1896-3811
Language: English
Page range: 1 - 15
Published on: Jun 22, 2018
Published by: Polish Biometric Society
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2018 Atanu Bhattacharjee, Vijay M. Patil, Vanita Noronha, Amit Joshi, Kumar Prabhash, published by Polish Biometric Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.